AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15911464 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir under constant exposure
Number of subjects: 703
Study 12097810 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 32
Study 12097810 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxyethylamphetamine (MDE)
Number of subjects: 32
Study 12097810 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methamphetamine
Number of subjects: 32
Study 12097810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9926195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (50 micrograms.kg‐1.min‐1)
Number of subjects: 10
Study 9926195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 10
Study 7572495 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dose (0.3 mmol/kg) of gadoteridol
Number of subjects: 85
Study 7572495 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (0.1 mmol/kg) of gadoteridol
Number of subjects: 85
Study 2405186 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 pmol vasoactive intestinal peptide
Number of subjects: 24
Study 2405186 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 pmol vasoactive intestinal peptide
Number of subjects: 24
Study 2405186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6108265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 57
Study 6108265 — intervention group
Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 57
Study 30823449 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg once a day (OD)
Number of subjects: 24
Study 30823449 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg twice a day (BID)
Number of subjects: 24
Study 28162215 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (40 mg parecoxib sodium IV before anesthetic induction, 0.375% ropivacaine 150 mg with dexamethasone 5 mg for transversus abdominis plane block)
Number of subjects: 90
Study 28162215 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Number of subjects: 90
Study 25835348 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (Prevacid; 30 mg)
Number of subjects: 21
Study 25835348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 24565236 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam added to lidocaine IVRA
Number of subjects: 45
Study 24565236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl added to lidocaine IVRA
Number of subjects: 45
Study 24565236 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine IVRA
Number of subjects: 45
Study 21222008 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cross linked porcine dermis biologic graft (Strattice(TM) Reconstructive Tissue Matrix)
Number of subjects: 172
Study 21222008 — intervention group
Group type: COMPARATOR
Intervention: Light weight, large pore polypropylene mesh (UltraPro(TM))
Number of subjects: 172
Study 20023244 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatain-Ibu foam dressing
Number of subjects: 40
Study 20023244 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing without healing promoting agent
Number of subjects: 40
Study 17086874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative manometry with mechanical calibration of the wrap
Number of subjects: 39
Study 17086874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraoperative manometry)
Number of subjects: 39
Study 15585901 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 38
Study 15585901 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing faster than normal or with eyes closed
Number of subjects: 38
Study 15585901 — intervention group
Group type: COMPARATOR
Intervention: Children with ADHD on medication
Number of subjects: 38
Study 15585901 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ADHD without medication
Number of subjects: 38
Study 15585901 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with ADHD
Number of subjects: 38
Study 11360779 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and pinning (group A)
Number of subjects: 28
Study 11360779 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and pinning (group B)
Number of subjects: 28
Study 9425640 — intervention group
Group type: EXPERIMENTAL
Intervention: levodropropizine syrup (60 mg t.i.d. for 5 days)
Number of subjects: 209
Study 9425640 — intervention group
Group type: COMPARATOR
Intervention: dextromethorphan syrup (15 mg t.i.d. for 5 days)
Number of subjects: 209
Study 8291876 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent self-catheterization (CIC) for 6 months
Number of subjects: 49
Study 8291876 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent self-catheterization (CIC) for 12 months
Number of subjects: 49
Study 8291876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CIC after urethrotomy)
Number of subjects: 49
Study 3318431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (2 g daily)
Number of subjects: 47
Study 3318431 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (1 g daily)
Number of subjects: 47
Study 30557397 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based physical activity (PA) integrated into math lessons for 9 months
Number of subjects: 505
Study 30557397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PA intervention)
Number of subjects: 505
Study 30557397 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based physical activity (PA)
Number of subjects: 505
Study 28576110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudo-Random Number Generator (PRNG) based on the k-logistic map
Number of subjects: 0
Study 28576110 — intervention group
Group type: EXPERIMENTAL
Intervention: k-logistic map
Number of subjects: 0
Study 28576110 — intervention group
Group type: EXPERIMENTAL
Intervention: chaotic maps
Number of subjects: 0
Study 25743367 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3x weekly)
Number of subjects: 42
Study 25743367 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 42
Study 23249842 — intervention group
Group type: COMPARATOR
Intervention: Grass silage supplemented with 4 kg concentrate daily
Number of subjects: 72
Study 23249842 — intervention group
Group type: COMPARATOR
Intervention: Grass silage supplemented with 8 kg concentrate daily
Number of subjects: 72
Study 23249842 — intervention group
Group type: COMPARATOR
Intervention: Maize silage (DM 217 g/kg) as sole forage supplemented with 4 kg concentrate daily
Number of subjects: 72
Study 23249842 — intervention group
Group type: COMPARATOR
Intervention: Maize silage (DM 304 g/kg) as sole forage supplemented with 4 kg concentrate daily
Number of subjects: 72
Study 23249842 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize silage (DM 217 g/kg) offered as 0.5 of the forage component of the diet supplemented with 4 kg concentrate daily
Number of subjects: 72
Study 23249842 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize silage (DM 304 g/kg) offered as 1.0 of the forage component of the diet supplemented with 4 kg concentrate daily
Number of subjects: 72
Study 20890207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g every 6 h)
Number of subjects: 196
Study 20890207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (1 g every 6 h)
Number of subjects: 196
Study 20890207 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg every 12 h)
Number of subjects: 196
Study 20890207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline every 6 h)
Number of subjects: 196
Study 18679820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (educational material and GP referral)
Number of subjects: 1133
Study 18679820 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1133
Study 16318049 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (neurontin)
Number of subjects: 34
Study 16318049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12452232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine titration in the PACU
Number of subjects: 80
Study 12452232 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine on demand every 6 hours
Number of subjects: 80
Study 10632080 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg HFA-beclomethasone dipropionate
Number of subjects: 23
Study 10632080 — intervention group
Group type: COMPARATOR
Intervention: 400 microg CFC-beclomethasone dipropionate
Number of subjects: 23
Study 9053973 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms every 6 hours for 7 days)
Number of subjects: 30
Study 9053973 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (25 mg three times a day for 7 days)
Number of subjects: 30
Study 9053973 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times a day for 7 days) + Misoprostol (200 micrograms every 6 hours for 7 days)
Number of subjects: 30
Study 1791771 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate plus 0.25 mg norgestrel (Cyclabil)
Number of subjects: 27
Study 1791771 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate plus 7.5 mg megestrol acetate (EV + MA)
Number of subjects: 27
Study 7043657 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg sulprostone four hourly with laminaria
Number of subjects: 120
Study 7043657 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg sulprostone four hourly without laminaria
Number of subjects: 120
Study 7043657 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg sulprostone eight hourly with laminaria
Number of subjects: 120
Study 7043657 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg sulprostone eight hourly without laminaria
Number of subjects: 120
Study 31807782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 43
Study 31807782 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 43
Study 29436397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdose education combined with a brief behavioural intervention and take-home naloxone
Number of subjects: 241
Study 29436397 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 241
Study 30772014 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-providing (IP) therapy
Number of subjects: 1021
Study 30772014 — intervention group
Group type: COMPARATOR
Intervention: Insulin-sensitizing (IS) therapy
Number of subjects: 1021
Study 28835167 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Anomaly Detection (MAD) by a static pole device
Number of subjects: 0
Study 28835167 — intervention group
Group type: COMPARATOR
Intervention: Continuous Wave Detection (CWD) by hand-held metal detector (HHMD)
Number of subjects: 0
Study 28835167 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Anomaly Detection (MAD)
Number of subjects: 0
Study 25989381 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Cap (medical topical treatment device)
Number of subjects: 40
Study 25989381 — intervention group
Group type: COMPARATOR
Intervention: Standard of care for nipple fissure treatment (control group)
Number of subjects: 40
Study 25989381 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Cap
Number of subjects: 40
Study 23038758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vinorelbine (Regimen B)
Number of subjects: 443
Study 23038758 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin, paclitaxel, and gemcitabine (Regimen A)
Number of subjects: 443
Study 22080794 — intervention group
Group type: EXPERIMENTAL
Intervention: Full prescription coverage
Number of subjects: 5845
Study 22080794 — intervention group
Group type: COMPARATOR
Intervention: Usual prescription coverage
Number of subjects: 5845
Study 20071891 — intervention group
Group type: EXPERIMENTAL
Intervention: cA-QOL (computerized asthma-specific quality-of-life questionnaire)
Number of subjects: 261
Study 20071891 — intervention group
Group type: COMPARATOR
Intervention: pA-QOL (paper-and-pencil asthma-specific quality-of-life questionnaire)
Number of subjects: 261
Study 20071891 — intervention group
Group type: EXPERIMENTAL
Intervention: cA-QOL
Number of subjects: 261
Study 20071891 — intervention group
Group type: COMPARATOR
Intervention: pA-QOL
Number of subjects: 261
Study 17014513 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance swab cultures (Ssc) with topical therapy based on Ssc results (Group A)
Number of subjects: 94
Study 17014513 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Group B)
Number of subjects: 94
Study 15486370 — intervention group
Group type: COMPARATOR
Intervention: Rollator
Number of subjects: 14
Study 11728946 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE D allele carriers
Number of subjects: 1454
Study 11728946 — intervention group
Group type: COMPARATOR
Intervention: ACE II homozygotes
Number of subjects: 1454
Study 9226386 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using expanded polytetraflouro‐ethylene (e‐PTFE) membrane
Number of subjects: 12
Study 9226386 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no membrane placed)
Number of subjects: 12
Study 8216395 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AUR)
Number of subjects: 200
Study 8216395 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 200
Study 8216395 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Auranofin and Methotrexate
Number of subjects: 200
Study 3624815 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 551
Study 3624815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 31185083 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of Orthodontic Treatment Need (IOTN) - Dental Health Component (DHC)
Number of subjects: 101
Study 31185083 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of Orthodontic Treatment Need (IOTN) - Aesthetic Component (AC)
Number of subjects: 101
Study 31185083 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of Complexity, Outcome, and Need (ICON)
Number of subjects: 101
Study 31185083 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Assessment Rating (PAR) index
Number of subjects: 101
Study 31185083 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Index of Orthodontic Treatment Need (CIOTN)
Number of subjects: 101
Study 31185083 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancy Index (DI)
Number of subjects: 101
Study 31185083 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial Aesthetic Index (FAI)
Number of subjects: 101
Study 28664541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study 28664541 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 540
Study 26645225 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 63
Study 26645225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 26645225 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 63
Study 26645225 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD patients and relatives
Number of subjects: 63
Study 24292557 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) consisting of 4, 5 min 200 mmHg balloon-cuff inflation/deflations to the upper arm.
Number of subjects: 362
Study 24292557 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo).
Number of subjects: 362
Study 24292557 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC).
Number of subjects: 362
Study 23643112 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise programme including depression awareness training for care-home staff and 45 min physiotherapist-led group exercise sessions delivered twice weekly.
Number of subjects: 891
Study 23643112 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise programme for residents depressed at baseline.
Number of subjects: 891
Study 20626146 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with blood-letting therapy
Number of subjects: 63
Study 20626146 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture only (Control)
Number of subjects: 63
Study 18975346 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 200 mg plus MTX
Number of subjects: 982
Study 18975346 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg plus MTX
Number of subjects: 982
Study 18975346 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 982
Study 16612487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum 900 mg/day
Number of subjects: 72
Study 16612487 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 72
Study 16612487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 14609153 — intervention group
Group type: EXPERIMENTAL
Intervention: IRB‐approved headgear (Canterbury Honeycomb model)
Number of subjects: 0
Study 14609153 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified headgear (altered dimensions with increased foam density and thickness)
Number of subjects: 0
Study 14609153 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard model headgear)
Number of subjects: 0
Study 11022584 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA testing
Number of subjects: 212
Study 11022584 — intervention group
Group type: COMPARATOR
Intervention: Repeat Pap test
Number of subjects: 212
Study 11022584 — intervention group
Group type: COMPARATOR
Intervention: Repeat Pap test showing ASCUS, LSIL or HSIL
Number of subjects: 212
Study 8863301 — intervention group
Group type: EXPERIMENTAL
Intervention: Real low-level laser treatment (4 x 6 J per treatment, 20 treatments total)
Number of subjects: 13
Study 8863301 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 13
Study 2031770 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 MU/m2 of rIFN-alpha, I.M., twice a week for six months
Number of subjects: 24
Study 2031770 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 MU/m2 of rIFN-alpha, I.M., twice a week for six months
Number of subjects: 24
Study 2031770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 24
Study 2031770 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha therapy (both dosages)
Number of subjects: 24
Study 392740 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 8
Study 392740 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylpenicillin
Number of subjects: 8
Study 31358645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural integration signaled through shared social norms
Number of subjects: 0
Study 31358645 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27672117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1061
Study 27672117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 25239078 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-free therapy (danoprevir/r 100/100mg, mericitabine 1000 mg, ribavirin 1000/1200 mg)
Number of subjects: 381
Study 25239078 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (danoprevir/r plus PegIFN alfa-2a/ribavirin)
Number of subjects: 381
Study 25239078 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad therapy (danoprevir/r, mericitabine, PegIFN alfa-2a/ribavirin)
Number of subjects: 381
Study 25239078 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-free therapy
Number of subjects: 381
Study 25239078 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad therapy (Quad 24)
Number of subjects: 381
Study 25239078 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad therapy (Quad 48)
Number of subjects: 381
Study 25239078 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad therapy (partial)
Number of subjects: 381
Study 25239078 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad therapy (null 24)
Number of subjects: 381
Study 25239078 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment failure
Number of subjects: 381
Study 25239078 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 381
Study 24057575 — intervention group
Group type: EXPERIMENTAL
Intervention: Currently screened (n = 3,498)
Number of subjects: 5193
Study 24057575 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdue (n = 418)
Number of subjects: 5193
Study 24057575 — intervention group
Group type: EXPERIMENTAL
Intervention: Never screened (n = 1,277)
Number of subjects: 5193
Study 24057575 — intervention group
Group type: COMPARATOR
Intervention: Measurement model validation
Number of subjects: 5193
Study 21548512 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 240
Study 21548512 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 240
Study 20076900 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh
Number of subjects: 32
Study 20076900 — intervention group
Group type: COMPARATOR
Intervention: Site-specific repair
Number of subjects: 32
Study 16409455 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation COC
Number of subjects: 35
Study 16409455 — intervention group
Group type: EXPERIMENTAL
Intervention: Third generation COC
Number of subjects: 35
Study 16409455 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations of COC
Number of subjects: 35
Study 16129293 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of lens epithelial cells (LECs) from the anterior capsule during cataract surgery
Number of subjects: 39
Study 16129293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no removal of LECs)
Number of subjects: 39
Study 12504937 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong irregular menstrual cycles
Number of subjects: 15253